Fig. 4: Inhibition of a single UPR pathway with specific inhibitors disrupts the refractive condition of the mouse eyes.
From: Scleral PERK and ATF6 as targets of myopic axial elongation of mouse eyes
a Effect of instillation of IRE1 inhibitor STF080310 (STF; 100 μM), PERK inhibitor GSK2656157 (GSK; 100 μM), and ATF6 inhibitor nelfinavir (NFV; 100 μM) on activation of the UPR pathways by LIM in sclerae. NL: No Lens control, −30D: minus 30 D lens-wearing eye. b Densitometric quantification of blots in Fig. 3a using ImageJ. DMSO-NL group was assigned a value of 1.0. Each group were n = 4 (each sample pooled 3 sclerae). The p values were determined by two-tailed Generalized Estimating Equations for four groups comparison (DMSO vs STF vs GSK vs NFV in each eyes) and Student’s two-tailed t-test for no lens (NL) and −30D lens (−30D) eyes comparison in each treatments. NS: Not Significant. c Effects of STF, GSK, and NFV instillation on axial elongation in NL and −30 D eyes (n = 5 per group); ***p < 0.001 compared to the DMSO group; two-tailed Generalized Estimating Equations. d Effects of STF, GSK, and NFV instillation on refraction in NL and −30 D eyes (n = 5 per group); **p < 0.01 (p = 0.001), ***p < 0.001compared to the DMSO group; two-tailed Generalized Estimating Equations. Source data are provided as a Source Data file.
